CONTEXT: - As circulating tumor cell (CTC) assays gain clinical relevance, it is essential to address preanalytic variability and to develop standard operating procedures for sample handling in order to successfully implement genomically informed, precision health care. OBJECTIVE: - To evaluate the effects of blood collection tube (BCT) type and time-to-assay (TTA) on the enumeration and high-content characterization of CTCs by using the high-definition single-cell assay (HD-SCA). DESIGN: - Blood samples of patients with early- and advanced-stage breast cancer were collected into cell-free DNA (CfDNA), EDTA, acid-citrate-dextrose solution, and heparin BCTs. Time-to-assay was evaluated at 24 and 72 hours, representing the fastest possible and more routine domestic shipping intervals, respectively. RESULTS: - We detected the highest CTC levels and the lowest levels of negative events in CfDNA BCT at 24 hours. At 72 hours in this BCT, all CTC subpopulations were decreased with the larger effect observed in high-definition CTCs and cytokeratin-positive cells smaller than white blood cells. Overall cell retention was also optimal in CfDNA BCT at 24 hours. Whole-genome copy number variation profiles were generated from single cells isolated from all BCT types and TTAs. Cells from CfDNA BCT at 24-hour TTA exhibited the least noise. CONCLUSIONS: - Circulating tumor cells can be identified and characterized under a variety of collection, handling, and processing conditions, but the highest quality can be achieved with optimized conditions. We quantified performance differences of the HD-SCA for specific preanalytic variables that may be used as a guide to develop best practices for implementation into patient care and/or research biorepository processes.
CONTEXT: - As circulating tumor cell (CTC) assays gain clinical relevance, it is essential to address preanalytic variability and to develop standard operating procedures for sample handling in order to successfully implement genomically informed, precision health care. OBJECTIVE: - To evaluate the effects of blood collection tube (BCT) type and time-to-assay (TTA) on the enumeration and high-content characterization of CTCs by using the high-definition single-cell assay (HD-SCA). DESIGN: - Blood samples of patients with early- and advanced-stage breast cancer were collected into cell-free DNA (CfDNA), EDTA, acid-citrate-dextrose solution, and heparin BCTs. Time-to-assay was evaluated at 24 and 72 hours, representing the fastest possible and more routine domestic shipping intervals, respectively. RESULTS: - We detected the highest CTC levels and the lowest levels of negative events in CfDNA BCT at 24 hours. At 72 hours in this BCT, all CTC subpopulations were decreased with the larger effect observed in high-definition CTCs and cytokeratin-positive cells smaller than white blood cells. Overall cell retention was also optimal in CfDNA BCT at 24 hours. Whole-genome copy number variation profiles were generated from single cells isolated from all BCT types and TTAs. Cells from CfDNA BCT at 24-hour TTA exhibited the least noise. CONCLUSIONS: - Circulating tumor cells can be identified and characterized under a variety of collection, handling, and processing conditions, but the highest quality can be achieved with optimized conditions. We quantified performance differences of the HD-SCA for specific preanalytic variables that may be used as a guide to develop best practices for implementation into patient care and/or research biorepository processes.
Authors: Libere J Ndacayisaba; Kate E Rappard; Stephanie N Shishido; Carmen Ruiz Velasco; Nicholas Matsumoto; Rafael Navarez; Guilin Tang; Pei Lin; Sonia M Setayesh; Amin Naghdloo; Ching-Ju Hsu; Carlisle Maney; David Symer; Kelly Bethel; Kevin Kelly; Akil Merchant; Robert Orlowski; James Hicks; Jeremy Mason; Elisabeth E Manasanch; Peter Kuhn Journal: Curr Oncol Date: 2022-04-21 Impact factor: 3.109
Authors: Stephanie N Shishido; Lisa Welter; Mariam Rodriguez-Lee; Anand Kolatkar; Liya Xu; Carmen Ruiz; Anna S Gerdtsson; Sara Restrepo-Vassalli; Anders Carlsson; Joe Larsen; Emily J Greenspan; E Shelley Hwang; Kathryn R Waitman; Jorge Nieva; Kelly Bethel; James Hicks; Peter Kuhn Journal: J Mol Diagn Date: 2020-01-22 Impact factor: 5.568
Authors: Robert L Grossman; Jonathan R Dry; Sean E Hanlon; Donald J Johann; Anand Kolatkar; Jerry S H Lee; Christopher Meyer; Lea Salvatore; Walt Wells; Lauren Leiman Journal: JCO Clin Cancer Inform Date: 2021-04
Authors: Stephanie N Shishido; Anders Carlsson; Jorge Nieva; Kelly Bethel; James B Hicks; Lyudmila Bazhenova; Peter Kuhn Journal: J Transl Med Date: 2019-08-28 Impact factor: 5.531
Authors: Drahomír Kolenčík; Sachin Narayan; Jana-Aletta Thiele; Dillon McKinley; Anna Sandström Gerdtsson; Lisa Welter; Petr Hošek; Pavel Ostašov; Ondřej Vyčítal; Jan Brůha; Ondřej Fiala; Ondřej Šorejs; Václav Liška; Pavel Pitule; Peter Kuhn; Stephanie N Shishido Journal: Cancers (Basel) Date: 2022-01-27 Impact factor: 6.639
Authors: Anna S Gerdtsson; Jana-Aletta Thiele; Stephanie N Shishido; Serena Zheng; Randolph Schaffer; Kelly Bethel; Steven Curley; Heinz-Josef Lenz; Diana L Hanna; Jorge Nieva; Anand Kolatkar; Carmen Ruiz; Mariam Rodriguez-Lee; Gerard J Oakley Iii; Jerry S H Lee; James Hicks; Peter Kuhn Journal: Oncotarget Date: 2019-12-17
Authors: Lisa Welter; Liya Xu; Dillon McKinley; Angel E Dago; Rishvanth K Prabakar; Sara Restrepo-Vassalli; Kevin Xu; Mariam Rodriguez-Lee; Anand Kolatkar; Rafael Nevarez; Carmen Ruiz; Jorge Nieva; Peter Kuhn; James Hicks Journal: Cold Spring Harb Mol Case Stud Date: 2020-12-17